UA88329C2 - Dna-pk inhibitors - Google Patents

Dna-pk inhibitors

Info

Publication number
UA88329C2
UA88329C2 UAA200704427A UAA200704427A UA88329C2 UA 88329 C2 UA88329 C2 UA 88329C2 UA A200704427 A UAA200704427 A UA A200704427A UA A200704427 A UAA200704427 A UA A200704427A UA 88329 C2 UA88329 C2 UA 88329C2
Authority
UA
Ukraine
Prior art keywords
optionally substituted
сalkyl
group
rand
сheterocyclyl
Prior art date
Application number
UAA200704427A
Other languages
English (en)
Inventor
Грейм Камерон Марри Смит
Нилл Моррисон Барр Мартин
Кейт Аллан Минер
Марк Джеффри Хаммерсон
Лоран Жан Мартен Ригоро
Роджер Джон Гриффин
Бернард Томас Голдинг
Девид Ричард Ньюэлл
Хилари Алан Калверт
Никола Джейн Кертин
Иан Роберт Хардкасл
Каппусами Сараванан
Original Assignee
Кудос Фармасьютикалз Лимитед
Кенсер Рисьёрч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кудос Фармасьютикалз Лимитед, Кенсер Рисьёрч Текнолоджи Лимитед filed Critical Кудос Фармасьютикалз Лимитед
Publication of UA88329C2 publication Critical patent/UA88329C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA200704427A 2004-09-20 2005-09-20 Dna-pk inhibitors UA88329C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61151504P 2004-09-20 2004-09-20

Publications (1)

Publication Number Publication Date
UA88329C2 true UA88329C2 (en) 2009-10-12

Family

ID=35610093

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200704427A UA88329C2 (en) 2004-09-20 2005-09-20 Dna-pk inhibitors

Country Status (16)

Country Link
US (3) US20070238731A1 (ru)
EP (1) EP1794151A1 (ru)
JP (1) JP2008513428A (ru)
KR (1) KR20070059156A (ru)
CN (1) CN101061111A (ru)
AU (1) AU2005286329A1 (ru)
BR (1) BRPI0515498A (ru)
CA (1) CA2580229A1 (ru)
IL (1) IL181969A0 (ru)
MX (1) MX2007003116A (ru)
NO (1) NO20071873L (ru)
RU (1) RU2408596C2 (ru)
TW (1) TW200616986A (ru)
UA (1) UA88329C2 (ru)
WO (1) WO2006032869A1 (ru)
ZA (1) ZA200703079B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
EP1551372B8 (en) 2002-09-20 2018-08-01 Alpharma Pharmaceuticals LLC Sequestering subunit and related compositions and methods
BRPI0413467A (pt) 2003-08-13 2006-10-17 Kudos Pharm Ltd aminopironas e seu uso como inibidoras da atm
EP1794151A1 (en) * 2004-09-20 2007-06-13 Kudos Pharmaceuticals Limited Dna-pk inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
JP2008542253A (ja) * 2005-05-26 2008-11-27 クドス ファーマシューティカルズ リミテッド Dna損傷癌療法に対してatm欠損癌を感作するためのdna−pk阻害の使用
UY29774A1 (es) * 2005-08-31 2007-03-30 Kudos Pharm Ltd Inhibidor de atm
EP2526932B1 (en) 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
AU2008338442A1 (en) * 2007-12-17 2009-06-25 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20110130386A1 (en) * 2008-04-25 2011-06-02 Mark Frigerio Dna-pk inhibitors
CA3142521A1 (en) 2019-06-17 2020-12-24 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2022133246A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1303724A (ru) 1969-05-14 1973-01-17
JPH0753725B2 (ja) * 1987-10-08 1995-06-07 富山化学工業株式会社 4h―1―ベンゾピラン―4―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
EP0459983A1 (en) 1988-12-21 1991-12-11 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en) * 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja) 1990-01-18 1991-09-20 Kyowa Hakko Kogyo Co Ltd 血管拡張剤
EP0525123B1 (en) 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
ATE128128T1 (de) 1990-06-29 1995-10-15 Upjohn Co Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
US5302613A (en) * 1990-06-29 1994-04-12 The Upjohn Company Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
US5252735A (en) * 1990-06-29 1993-10-12 The Upjohn Company Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1994005283A1 (en) 1992-09-02 1994-03-17 Kyowa Hakko Kogyo Co., Ltd. Anti-hiv drug
CA2159192C (en) 1993-04-09 2006-07-25 Keiichi Tanaka Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en) 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
GB9521987D0 (en) 1995-10-26 1996-01-03 Ludwig Inst Cancer Res Phosphoinositide 3-kinase modulators
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
WO1997018323A2 (en) 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
GB2302021A (en) 1996-10-16 1997-01-08 Lilly Co Eli Inhibiting bone loss or resorption
WO1998055602A1 (en) 1997-06-06 1998-12-10 Mayo Foundation For Medical Education And Research Screening for phosphatidylinositol related-kinase inhibitors
WO1998056391A1 (en) 1997-06-13 1998-12-17 President And Fellows Of Harvard College Methods for treating human cancers
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6387640B1 (en) * 1999-02-10 2002-05-14 St. Jude Children's Research Hospital ATM kinase modulation for screening and therapies
US6348311B1 (en) * 1999-02-10 2002-02-19 St. Jude Childre's Research Hospital ATM kinase modulation for screening and therapies
US6333180B1 (en) * 1999-12-21 2001-12-25 International Flavors & Fragrances Inc. Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate
ATE363471T1 (de) 2000-01-24 2007-06-15 Astrazeneca Ab Durch einen morpholinrest substituierte therapeutische verbindungen
PL365694A1 (en) * 2000-06-28 2005-01-10 Teva Pharmaceutical Industries Ltd. Carvedilol
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
JP4458746B2 (ja) 2001-01-16 2010-04-28 グラクソ グループ リミテッド 癌の治療方法
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119863D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
AU2002349912A1 (en) 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
WO2003034997A2 (en) 2001-10-24 2003-05-01 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CA2473100A1 (en) 2002-02-25 2003-08-28 Kudos Pharmaceuticals Limited Pyranones useful as atm inhibitors
JP4500161B2 (ja) * 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
BRPI0413467A (pt) * 2003-08-13 2006-10-17 Kudos Pharm Ltd aminopironas e seu uso como inibidoras da atm
EP1794151A1 (en) 2004-09-20 2007-06-13 Kudos Pharmaceuticals Limited Dna-pk inhibitors
TW200638938A (en) * 2005-02-09 2006-11-16 Kudos Pharm Ltd ATM inhibitors
AR053358A1 (es) * 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
UY31232A1 (es) * 2007-07-19 2009-03-02 Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

Also Published As

Publication number Publication date
BRPI0515498A (pt) 2008-07-29
CA2580229A1 (en) 2006-03-30
US7732483B2 (en) 2010-06-08
US20060106025A1 (en) 2006-05-18
KR20070059156A (ko) 2007-06-11
RU2007110629A (ru) 2008-10-27
MX2007003116A (es) 2007-07-16
CN101061111A (zh) 2007-10-24
RU2408596C2 (ru) 2011-01-10
US7402607B2 (en) 2008-07-22
EP1794151A1 (en) 2007-06-13
AU2005286329A1 (en) 2006-03-30
US20070238731A1 (en) 2007-10-11
NO20071873L (no) 2007-06-15
TW200616986A (en) 2006-06-01
JP2008513428A (ja) 2008-05-01
ZA200703079B (en) 2008-08-27
IL181969A0 (en) 2007-07-04
US20080242664A1 (en) 2008-10-02
WO2006032869A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
UA88329C2 (en) Dna-pk inhibitors
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
UA95978C2 (ru) Ингибитор активации stat3/5
RS53451B (en) INHIBITORI P70 S6 KINAZE
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
NO20074057L (no) 2,4-Diaminopyridopyrimidinderivater og deres anvendelse som mTOR-inhibitorer
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
MX2011008305A (es) Compuestos de piridazinona.
HK1069827A1 (en) Pyranones useful as atm inhibitors.
MX2009005217A (es) Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos.
TW200612920A (en) Novel imidazolidine derivatives
TW200611907A (en) Fused heterocyclic compound
UA95972C2 (ru) Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а
EP1724258A4 (en) HETEROARYLPHENYLUREE DERIVATIVE
TW200602319A (en) Indole derivative and use thereof
TW200609218A (en) Bicyclic compounds
RS20060315A (en) Derivatives of n-/phenyl(pyrrolidine-2-yl) methyl/benzamide, and n- /(azepan-2-yl)phenylmethyl/benzamide, preparation method thereof and application of same in therapeutics
TW200716650A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
TW200613289A (en) Prodrugs of hiv protease inhibitors
MY169179A (en) Novel piperidine compound or salt thereof
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
IL180171A0 (en) Novel 2-substituted d-homo-estra-1,3,5(10)-trienes as inhibitors of 17??- hydroxysteroid dehydrogenase type 1
MX2010001566A (es) Derivado de aminopirazolamida.
TW200745104A (en) Multikinase inhibitor
TW200640462A (en) Compounds